SOUTH SAN FRANCISCO, Calif.,
June 2, 2016 /PRNewswire/ -- Rigel
Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that
Ryan Maynard, the company's chief
financial officer, is scheduled to present a company overview at
the Jefferies 2016 Healthcare Conference in New York City on Thursday, June 9th at 10:30 am ET.
To access the live audio webcast or the subsequent archived
recording, log on to www.rigel.com. Please connect to Rigel's
website several minutes prior to the start of the live webcast to
ensure adequate time for any software download that may be
necessary.
About Rigel (www.rigel.com)
Rigel Pharmaceuticals,
Inc. is a clinical-stage biotechnology company dedicated to the
discovery and development of novel, targeted drugs in the
therapeutic areas of immunology, oncology and immuno-oncology.
Rigel's pioneering research focuses on signaling pathways that are
critical to disease mechanisms. The company's current clinical
programs include fostamatinib, an oral spleen tyrosine kinase (SYK)
inhibitor, which is in Phase 3 clinical trials for ITP; a Phase 2
clinical trial for autoimmune hemolytic anemia (AIHA); and a Phase
2 clinical trial for IgA nephropathy (IgAN). In addition, Rigel has
two oncology product candidates in Phase 1 development with
partners BerGenBio AS and Daiichi Sankyo.
Contact: Ryan Maynard
Phone: 650.624.1284
Email: invrel@rigel.com
Media Contact: Susan C. Rogers,
Rivily, Inc.
Phone: 650.430.3777
Email: susan@rivily.com
Logo - http://photos.prnewswire.com/prnh/20030226/RIGLLOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/rigel-to-present-at-jefferies-2016-healthcare-conference-300278451.html
SOURCE Rigel Pharmaceuticals, Inc.